Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

Erselcan, 2000, Subclinical cardiotoxicity following adjuvant dose escalated FEC, high-dose chemotherapy, or CMF in breast cancer, Br J Cancer, 82, 777, 10.1054/bjoc.1999.0998 Frishman, 1996, Cardiovascular toxicity with cancer chemotheraphy, Curr Prob Cardiol, 21, 225, 10.1016/S0146-2806(96)80011-9 Wojtacki, 2000, Anthracycline-induced cardiotoxicity, Med Sci Monit, 6, 411 Mladosievicova, 1994, Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents, Bratisl Lek Listy, 95, 304 Hrdina, 2000, Anthracycline-induced cardiotoxicity, Acta Med, 43, 75 Swain, 2003, Congestive heart failure in patients treated with doxubicin, Cancer, 97, 2869, 10.1002/cncr.11407 Kremer, 1999, Indium-111 antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children, J Clin Oncol, 4, 1208, 10.1200/JCO.1999.17.4.1208 Lipshultz, 1997, Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury, Circulation, 96, 2641, 10.1161/01.CIR.96.8.2641 Iarussi, 2000, Cardiac toxicity after anthracycline chemotherapy in childhood, Herz, 25, 676, 10.1007/PL00001982 Elbl, 1999, Changes in left ventricular function during chemotherapy with doxorubucin, Vnitr Lek, 45, 395 Lluch, 2000, Doxorubicin and placlitaxel in advanced breast carcinoma, Cancer, 89, 2169, 10.1002/1097-0142(20001201)89:11<2169::AID-CNCR4>3.0.CO;2-9 Benvenuto, 2000, Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors, Ital Heart J, 1, 1457 Morandi, 2001, Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide, Bone Marrow Trasplant, 28, 277, 10.1038/sj.bmt.1703132 Cersosimo, 1986, Epirubicin, J Clin Oncol, 4, 425, 10.1200/JCO.1986.4.3.425 Dazzi, 2001, Ann Oncol, 12, 963, 10.1023/A:1011196910325 Cardinale, 2002, Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy, Ann Oncol, 13, 710, 10.1093/annonc/mdf170 Cardinale, 2000, Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy, J Am Coll Cardiol, 36, 517, 10.1016/S0735-1097(00)00748-8 Aviles, 2000, Second lethal events associated with treatment for Hodgkin’s disease, Leuk Lymphoma, 39, 311, 10.3109/10428190009065830 Auner, 2002, Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high dose cyclophosphamide, Eur J Hematol, 69, 1, 10.1034/j.1600-0609.2002.01661.x Auner, 2003, Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies, Ann Hematol, 82, 218, 10.1007/s00277-003-0615-3 Singal, 1998, Doxorubicin-induced cardiomyopathy, N Engl J Med, 339, 900, 10.1056/NEJM199809243391307 Torti, 1986, Cardiotoxicity of epirubicin and doxorubicin, Cancer Res, 46, 3722 Ganz, 1996, Review of tests for monitoring doxorubicin-induced cardiomyopathy, Oncology, 53, 461, 10.1159/000227621 Ricchiuti, 1998, Cardiac troponin T isoforms expressed in renal disease skeletal muscle will not cause false- positive results by the second generation cardiac troponin T assay by Boehringer Mannheim, Clin Chem, 44, 1919, 10.1093/clinchem/44.9.1919 Muller-Bardorff, 1997, Improved troponin T Elisa specific for cardiac troponin T isoform, Clin Chem, 43, 458, 10.1093/clinchem/43.3.458 Panteghini, 1999, The sensitivity of cardiac markers, Clin Chem Lab Med, 37, 1097, 10.1515/CCLM.1999.160 Herman, 1999, Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin, J Clin Oncol, 17, 2237, 10.1200/JCO.1999.17.7.2237 Missov, 1997, Cardiac troponin I in patients with hematologic malignancies, Coron Artery Dis, 8, 537 Sparano, 2000, Troponins for predicting cardiotoxicity from cancer therapy, Lancet, 356, 1947, 10.1016/S0140-6736(00)03304-3 Bennet, 1976, Proposals for the classification of the acute leukemias, Br J Haematol, 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Bene, 1995, Leukemia, 9, 1783 Katrukha Aleksei, 1998, Degradation of cardiac troponin I, Clin Chem, 44;, 2433, 10.1093/clinchem/44.12.2433 Panteghini, 2001, Quality specifications for cardiac troponin assays, Clin Chem Lab Med, 39, 174, 10.1515/cclm.2001.39.2.175 2000, Myocardial infarction redefined, J Am Coll Cardiol, 36, 959, 10.1016/S0735-1097(00)00804-4 Gaudin, 1993, Myocarditis associated with doxorubicin cardiotoxicity, Am J Clin Pathol, 100, 158, 10.1093/ajcp/100.2.158 Carlson, 1992, Reducing the cardiotoxicity of the anthracyclines, Oncology, 6, 95 Meinardi, 1999, Detection of anthracycline-induced cardiotoxicity, Cancer Treat Rev, 25, 237, 10.1053/ctrv.1999.0128 Wu, 1999, Release of cardiac troponin in acute coronary syndromes, Clin Chim Acta, 284, 161, 10.1016/S0009-8981(99)00078-9 Collinson, 2001, Measurement of cardiac troponins, Ann Clin Biochem, 38, 423, 10.1258/0004563011901109 Wayand, 2000, Cardiac troponin T and I in end stage renal failure, Clin Chem, 46, 1345, 10.1093/clinchem/46.9.1345 Grenier, 1998, Epidemiology of anthracycline cardiotoxicity in children and adults, Semin Oncol, 25, 72 Li, 2003, The effect of age on the early disposition of doxorubicin, Cancer Chemother Pharmacol, 51, 395, 10.1007/s00280-002-0554-z Sugimoto, 1992, Molecular cloning and characterization of the platelet-activating factor gene, Res Commun, 189, 617 Ligget, 1998, The Ile 164 beta-adrenergic receptor polymorphism adversely affects the outcome of the congestive heart failure, J Clin Invest, 102, 1534, 10.1172/JCI4059 Budman, 2001, In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy, Leukemia, 15, 1517, 10.1038/sj.leu.2402244 Safra, 2000, Pegylated liposomal doxorubicin (doxil), Ann Oncol, 11, 1029, 10.1023/A:1008365716693